Avigan Trial Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Avigan trial study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Avigan Trial Study Today - Breaking & Trending Today

Dr. Reddys and GRA announces Avigan Pivotal Studies Update

Posted on
895
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical program for Avigan, spanning the spectrum of Asymptomatic to severe cases of COVID in both outpatient and in-patient setting. The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr. Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue. ....

United Arab Emirates , United States , Appili Therapuetics , Exchange Commission , Holdings Corporation , Services Active Ingredients , Reddy Laboratories Ltd , Toyama Chemical Co Ltd , Global Response Aid , Avigan Trial Study , North America , Pharmaceutical Services , Active Ingredient , Global Generics , Proprietary Products , Annual Report , Appili Therapeutics , ஒன்றுபட்டது அரபு அமீரகங்கள் , ஒன்றுபட்டது மாநிலங்களில் , பரிமாற்றம் தரகு , ஹோல்டிங்ஸ் நிறுவனம் , சேவைகள் செயலில் பொருட்கள் , சிவப்பு ஆய்வகங்கள் லிமிடெட் , டோயாமா இரசாயன இணை லிமிடெட் , உலகளாவிய பதில் உதவி , வடக்கு அமெரிக்கா ,

Dr Reddy's, GRA terminate Avigan study on hospitalised Covid cases in Kuwait

Dr Reddy’s, GRA terminate Avigan study on hospitalised Covid cases in Kuwait
January 27, 2021
×
Dr Reddy’s Laboratories Ltd and Global Response Aid FZCO (GRA) on Wednesday announced the termination of an Avigan Trial Study conducted in Kuwait focussed on moderate to severe Covid patients in a hospital setting.
The hospitalised patient study was one of the studies in the overall clinical programme for Avigan, spanning the spectrum of asymptomatic to severe cases of Covid in both outpatient and in-patient settings.
Avigan is a trademark of Fujifilm Toyama Chemical Co Ltd.
The Phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by Dr Reddy’s, in partnership with Appili Therapuetics and Global Response Aid, shall continue. ....

United States , Appili Therapuetics , Fujifilm Toyama Chemical Co Ltd , Dr Reddy Laboratories Ltd , Laboratories Ltd , Global Response Aid , Avigan Trial Study , North America , Appili Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , புஜிஃபில்ம் டோயாமா இரசாயன இணை லிமிடெட் , டாக்டர் சிவப்பு ஆய்வகங்கள் லிமிடெட் , ஆய்வகங்கள் லிமிடெட் , உலகளாவிய பதில் உதவி , வடக்கு அமெரிக்கா ,

Dr Reddy's, GRA announces termination of Avigan Pivotal study for hospitalized moderate to severe Covid patients in Kuwait

Business EconomyPosted at: Jan 27 2021 4:12PM
Dr Reddy’s, GRA announces termination of Avigan Pivotal study for hospitalized moderate to severe Covid patients in Kuwait
Hyderabad, Jan 27 (UNI) Dr Reddy’s Laboratories Ltd and Global Response Aid FZCO (GRA) on Wednesday announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
While study for out-patient mild to moderate cases continues in North America, the Hyderabad-based Pharmaceutical giant said in a statement here.
The hospitalized patient study, conducted in Kuwait, on moderate to severe patients was one of the studies in the overall clinical program for Avigan, spanning the spectrum of Asymptomatic to severe cases of COVID in both outpatient and in-patient settings. ....

United States , Andhra Pradesh , Dr Reddy Lab , Dr Reddy Laboratories Ltd , Avigan Pivotal , Laboratories Ltd , Global Response Aid , Avigan Trial Study , North America , Hyderabad Based Pharmaceutical , Appili Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , ஆந்திரா பிரதேஷ் , டாக்டர் சிவப்பு ஆய்வகம் , டாக்டர் சிவப்பு ஆய்வகங்கள் லிமிடெட் , ஆய்வகங்கள் லிமிடெட் , உலகளாவிய பதில் உதவி , வடக்கு அமெரிக்கா , ஹைதராபாத் அடிப்படையிலானது மருந்து ,

Dr. Reddy's, GRA End Avigan Study Conducted In Kuwait On Moderate To Severe COVID Patients

(1)
NEW DELHI (dpa-AFX) - Dr. Reddy s Laboratories Ltd. (RDY) and Global Response Aid FZCO announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting. The data from the study did not show statistically significant difference for the primary endpoint for Avigan vs. Placebo.
Dr. Reddy s said the phase-III study, being conducted in an outpatient setting on patients with mild to moderate symptoms in North America by the company, in partnership with Appili Therapuetics and Global Response Aid, shall continue.
Copyright RTT News/dpa-AFX
© 2021 AFX News ....

United States , Appili Therapuetics , Reddy Laboratories Ltd , Global Response Aid , Avigan Trial Study , North America , ஒன்றுபட்டது மாநிலங்களில் , சிவப்பு ஆய்வகங்கள் லிமிடெட் , உலகளாவிய பதில் உதவி , வடக்கு அமெரிக்கா ,